Liver Cancer

Patients with advanced HCC who progressed after treatment with immunotherapy may have a survival benefit when treated with second-line Lenvima.

Good science, along with creativity in applying and testing it properly, can be successful against all odds for patients with cholangiocarcinoma.

If approved by the FDA, zanidatamab could be the first HER-2 targeted therapy for patients with biliary tract cancers.

Biliary duct cancer, or cholangiocarcinoma, has always been known as a difficult-to-treat disease, but immunotherapies may make an impact on patients' lives.

The FDA approved Imjudo plus Imfinzi for advanced hepatocellular carcinoma, although more work is needed to develop a treatment that cures patients, an expert said.

The dual immunotherapy regimen of Imjudo and Imfinzi may provide patients with unresectable hepatocellular carcinoma a well-tolerated treatment to extend survival.

The Food and Drug Administration approved Imfinzi plus gemcitabine and cisplatin for locally advanced or metastatic biliary tract cancer.

From “EastEnders” star Samantha Womack announcing her breast cancer diagnosis in a tribute to Olivia Newton-John to a famous fashion designer’s death from liver cancer, here’s what’s happening in the oncology space this week.

Treatment with Keytruda plus Lenvima did not best Lenvima alone as a first-line treatment option for a group of patients with liver cancer that could not be treated with surgery, according to recently announced study results from a phase 3 clinical trial.

Shrinking liver cancer tumors helps patients become eligible for transplant, thus improving their long-term outcomes, according to recent study results.

From actors Tony Dow and David Warner dying from cancer to a cancer survivor rappelling a building in the name of awareness and fundraising, here’s what’s happening in the oncology space this week.

Treatment with Opdivo plus standard of care chemotherapy followed by maintenance Opdivo or Opdivo plus Yervoy failed to elicit survival benefits compared with standard of care chemotherapy alone in patients with previously untreated advanced biliary cancer, which is a rare form of liver cancer.

Treatment with Cabometyx in combination with Tecentriq induced superior progression-free survival outcomes and disease control rates versus Nexavar alone in patients with advanced hepatocellular carcinoma, the most common type of liver cancer.

From “General Hospital” star Cameron Mathison discussing his cancer experience to Dame Deborah James and Hells Angels founder Sonny Barger dying of the disease, here’s what happened in the cancer space this week.

Treatment with an experimental drug delivered through a minimally invasive procedure may show promise in patients with liver cancer that cannot be treated with surgery.

Although she has always been driven to excel, Karen Driskill's, M.S., RN, purpose became more focused after her mother-in-law passed away from intrahepatic cholangiocarcinoma in 2010.

The priority review means that the FDA plans to speed up its review of Imfinzi combined with chemotherapy in patients with advanced or metastatic biliary tract cancer.

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of immunotherapy from palliative treatment in the metastatic setting to curative treatment in localized disease,” the study authors wrote.

The FDA plans to decide on whether to approve futibatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma that harbors a certain genetic mutation by September.

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

The combination of Cabometyx and Tecentriq failed to improve overall survival in patients with advanced hepatocellular carcinoma, the most common type of primary liver cancer, compared with single-agent Tecentriq or Nexavar.

Treatment with a combination of PD-1 inhibition, minimally invasive chemotherapy and Lenvima improved outcomes for patients with unresectable liver cancer compared to PD-1 inhibition and Lenvima alone.

A woman whose husband died from cancer explains how she shattered a piece of pottery and glued it back together, to represent the cracks of her life left by her loss and how her husband remains connected to her.

An expert from Memorial Sloan Kettering Cancer Center in New York discusses the promising findings from a study that analyzed tremelimumab plus Imfinzi for unresectable hepatocellular carcinoma, and outlines side effects patients should discuss with their doctor.

Patients with biliary tract cancer achieved a better survival outcome after receiving treatment with an oral antimetabolite following surgical resection than patients who only were treated with surgery.

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.

Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.